• The decline follows NeuroSense Therapeutics' July 30, 2026, filing of a $150 million securities shelf offering, which permits the company to offer various securities and could lead to significant share dilution.
  • The related SEC filing included an auditor's explanatory paragraph citing substantial doubt about NeuroSense's ability to continue as a going concern, adding to investor concerns.
  • This comes as the stock also faces continued weakness, with a prior bargain-hunting rebound losing momentum amid a challenging broader biotechnology sector.